(4R)-thiazolidine-4-carboxamide | 61434-84-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (4R)-thiazolidine-4-carboxamide
• 英文别名: L-thiazolidine-4-carboxamide；Tzl-NH2；(R)-4-carbamoylthiazolidine；(R)-thiazolidine-4-carboxylic acid amide；N,S-methanediyl-L-cysteine amide；(R)-thiazolidine-4-carboxylic acid amide；(4r)-1,3-Thiazolidine-4-carboxamide
• CAS: 61434-84-2
• 化学式: C₄H₈N₂OS
• 分子量: 132.186
• InChiKey: AIOMGEMZFLRFJE-VKHMYHEASA-N

物化性质

• 沸点：
  406.8±40.0 °C(Predicted)
• 密度：
  1.287±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  80.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (4R)-thiazolidine-4-carboxamide 在 1-羟基苯并三唑 N-甲基吗啉 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 18.5h， 生成 tert-butyl (2S,3S,5S)-5-{[(4R)-4-carbamoyl-1,3-thiazolidin-3-yl]carbonyl}-2-methyl-3-{[4-(3-methyl-1,2,4-thiadiazol-5-yl)piperazin-1-yl]carbonyl}pyrrolidine-1-carboxylate
  参考文献：
  名称：

  WO2006/73167

  摘要：

  公开号：
• 作为产物：
  描述：

  (R)-噻唑烷-4-甲酸甲酯 在 氨 作用下， 以 甲醇 为溶剂， 反应 24.0h， 生成 (4R)-thiazolidine-4-carboxamide
  参考文献：
  名称：

  Study of the structural requirements for Dopa potentiation and oxotremorine antagonism by L-prolyl-L-leucylglycinamide

  摘要：

  A number of analogs of the tripeptide L-prolyly-L-leucylglycinamide (1) were synthesized and evaluated in the Dopa potentiation and oxotremorine antagonism tests. The replacement of the glycinamide residue with either the glycine methylamide, glycine, aminoacetonitrile, amino-2-propanone, semicarbazide, or beta-alaninamide residues resulted in a loss of activity in both tests. A 1:1 mixture of L-prolyl-L-leucyl-(-)-thiazolidine-2-carboxamide (8) and L-prolyl-L-leucyl-(+)-thiazolidine-2-carboxamide (9) showed marked activity in the Dopa potentiation test but was unable to antagonize the tremors induced by oxotremorine. L-Prolyl-L-leucyl-L-prolinamide (11), on the other hand, was active in the oxotremorine antagonism test but inactive in the Dopa potentiation test. The replacement of the pyrrolidine ring of 1 with either a thiazolidine or cyclopentane ring system caused a loss of activity. The cyclopentanecarboxylic acid analogue 13, however, was found to have moderate activity in the serotonin potentiation test.

  DOI：

  10.1021/jm00200a004

文献信息

• DIPEPTIDYL PEPTIDASE IV INHIBITOR
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP1354882A1

  公开（公告）日：2003-10-22

  A compound represented by general formula (I):         A-B-D or a pharmacologically acceptable salt thereof.

  一个由通用式(I)表示的化合物：         A-B-D <其中 A代表取代或未取代的1-吡咯烷基、取代或未取代的3-噻唑烷基、取代或未取代的1-氧代-3-噻唑烷基等； B代表a)由-(C(R1)(R2))kCO-（其中k表示1至6的整数，R1和R2可以相同也可以不同，每个代表氢原子、羟基、卤素原子等）等的基团； D代表-U-V [其中U代表取代或未取代的哌嗪基团等，V代表-E-R7（其中E代表单键、-CO-、-C(=O)O-或-SO2-；R7代表氢原子、取代或未取代的烷基等）] >或其药理学上可接受的盐。
• Dicyclooctane Derivatives, Preparation Processes and Medical Uses Thereof
  申请人：Tang Peng Cho

  公开号：US20090176847A1

  公开（公告）日：2009-07-09

  The present invention relates to new dicyclooctane derivates represented by general formula (I), preparation processes and pharmaceutical compositions containing them, and to uses for treatment especially for dipeptidyl peptidase inhibitor (DPPIV), in which each substituent group of general formula (I) is as defined in specification.

  本发明涉及由通式（I）表示的新二环辛烷衍生物，其制备方法和含有它们的药物组合物，以及用于治疗尤其是二肽基肽酶抑制剂（DPPIV）的用途，其中通式（I）的每个取代基如规范中所定义。
• Organic Compounds
  申请人：Caravatti Giorgio

  公开号：US20090163469A1

  公开（公告）日：2009-06-25

  The present invention relates to compounds of formula I and its salts, wherein the substituents are as defined in the description, to compositions and use of the compounds in the treatment of diseases ameloriated by inhibition of phosphatidylinositol 3-kinase.

  本发明涉及公式I的化合物及其盐，其中取代基如描述中所定义，以及该化合物在治疗通过抑制磷脂酰肌醇3-激酶改善的疾病中的应用。
• Synthesis and central nervous system actions of thyrotropin-releasing hormone analogs containing a 1-oxo-1,2,3,4-tetrahydroisoquinoline moiety.
  作者：HIROSHI MAEDA、MAMORU SUZUKI、HIROSHI SUGANO、MICHIO MAYAMURA、RYUICHI ISHIDA

  DOI：10.1248/cpb.36.190

  日期：——

  In order to find compounds having selective central nervous system (CNS) actions, various thyrotropin-releasing hormone (TRH) analogs in which the pyroglutamic acid residue is replaced by (3S)-1-oxo-1, 2, 3, 4-tetrahydroisoquinoline-3-carboxylic acid (Otc-OH) and related derivatives were prepared and their CNS actions were investigated in mice.Otc-His-Pro-NH2 (9a) showed 3.5-10 times stronger CNS actions than TRH (1). However, it was also 3-4 times more potent than TRH in thyrotropin (TSH)-releasing activity.

  为了寻找具有选择性中枢神经系统 (CNS) 作用的化合物，合成了各种促甲状腺激素释放激素 (TRH) 类似物，其中将吡咯谷氨酸残基替换为 (3S)-1-氧代-1, 2, 3, 4-四氢异喹啉-3-羧酸 (Otc-OH) 及相关衍生物，并在小鼠中研究了它们的 CNS 作用。Otc-His-Pro-NH2 (9a) 的 CNS 作用比 TRH (1) 强 3.5 到 10 倍。然而，在促甲状腺激素 (TSH) 释放活性方面，它的效力比 TRH 强 3 到 4 倍。
• Synthesis of thyrotropin-releasing hormone analogs with selective central nervous system effects
  作者：Ruth F. Nutt、Frederick W. Holly、Carl Homnick、Ralph Hirschmann、Daniel F. Veber、Byron H. Arison

  DOI：10.1021/jm00138a010

  日期：1981.6

  Thyrotropin-releasing hormone (TRH) analogues which show relative selectivity for action in the central nervous system have been recognized. Practical syntheses for three of these TRH analogues which show the greatest selectivity, less than Aad-His-Tzl-NH2 (5), less than Glu-His-Pip-OMe (2), and less than Aad-His-Pro-NH2 (6), are described. The first two were prepared by solution methods of peptide

  促甲状腺激素释放激素（TRH）类似物在中枢神经系统中显示出相对的选择性。三种TRH类似物的实用合成物显示出最高的选择性，低于Aad-His-Tzl-NH2（5），低于Glu-His-Pip-OMe（2）和低于Aad-His-Pro-NH2 （6），有描述。前两种是通过肽合成的溶液方法制备的。通过固相方法制备化合物6。为了获得最佳收率，组氨酸外消旋化，容易的二酮哌嗪形成和酰化的噻唑烷羧酸衍生物在酸性条件下的不稳定性问题已被最小化。已检查了诸如pK，NMR位移和圆二色性等物理性质，因为它们可能与生物学活性和肽构象有关。